-
1Academic Journal
Συγγραφείς: J. A. Agafonova, Ю. А. Агафонова
Πηγή: FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology; Vol 18, No 2 (2025); 164–174 ; ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология; Vol 18, No 2 (2025); 164–174 ; 2070-4933 ; 2070-4909
Θεματικοί όροι: ABC/VEN-анализ, anticancer therapy, oral drugs, pharmacoeconomics, ABC/VEN analysis, противоопухолевая терапия, пероральные препараты, фармакоэкономика
Περιγραφή αρχείου: application/pdf
Relation: https://www.pharmacoeconomics.ru/jour/article/view/1226/618; Global oncology trends 2024: outlook to 2028. Annual trend report from the IQVIA Institute for Human Data Science. May 28, 2024. Available at: https://www.iqvia.com/insights/the-iqvia-institute/reports-andpublications/reports/global-oncology-trends-2024 (accessed 25.04.2025).; Schaft N., Dörrie J., Schuler G., et al. The future of affordable cancer immunotherapy. Front Immunol. 2023; 14: 1248867. https://doi.org/10.3389/fimmu.2023.1248867.; Naci H., Zhang Y., Woloshin S., et al. Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis. Lancet Oncol. 2024; 25 (6): 760–9. https://doi.org/10.1016/S14702045(24)00152-9.; Del Paggio J.C., Sullivan R., Schrag D., et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017; 18 (7): 887–94. https://doi.org/10.1016/S1470-2045(17)30415-1.; Laviana A.A., Luckenbaugh A.N., Resnick M.J. Trends in the cost of cancer care: beyond drugs. J Clin Oncol. 2020; 38 (4): 316–22. https://doi.org/10.1200/JCO.19.01963.; Всемирная организация здравоохранения. Методы анализа использования лекарств и расходов на содействие осуществлению лекарственной политики. URL: https://iris.who.int/bitstream/handle/10665/342858/9789289055697-rus.pdf?sequence=1&isAllowed=y (дата обращения 25.0.2025).; Жукова О.В., Руина О.В., Хазов М.В. и др. Фармакоэпидемиологический анализ потребления лекарственных препаратов в многопрофильном стационаре – элемент управления качеством медицинской помощи и основа оценки импортозамещения. ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2022; 15 (1): 51–8. https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.046.; Pantziarka P., Capistrano I R., De Potter A., et al. An open access database of licensed cancer drugs. Front Pharmacol. 2021; 12: 627574. https://doi.org/10.3389/fphar.2021.627574.; World Health Organization. Model List of Essential Medicines. Available at: https://list.essentialmeds.org/ (accessed 25.04.2025).; Jenei K., Aziz Z., Booth C., et al. Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward. Lancet Glob Health. 2022; 10 (12): e1860–6. https://doi.org/10.1016/S2214-109X(22)00376-X.; Коробейникова А.Н., Мальчикова С.В. ABC-, VEN- и частотный анализ терапии фибрилляции предсердий в условиях «типичной практики». ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология. 2015; 8 (4): 28–31. https://doi.org/10.17749/2070-4909.2015.8.4.028-031.; Zhou Y., Naci H., Chen D., et al. Overall survival benefits of cancer drugs in the WHO Model List of Essential Medicines, 2015–2021. BMJ Glob Health. 2023; 8 (9): e012899. https://doi.org/10.1136/bmjgh-2023-012899.; Yang Y.T., Nagai S., Chen B.K., et al. Generic oncology drugs: are they all safe? Lancet Oncol. 2016; 17 (11): e493–501. https://doi.org/10.1016/S1470-2045(16)30384-9.; Cheung W.Y., Kornelsen E.A., Mittmann N., et al. The economic impact of the transition from branded to generic oncology drugs. Curr Oncol. 2019; 26 (2): 89–93. https://doi.org/10.3747/co.26.4395.; Yabroff K.R., Mariotto A., Tangka F., et al. Annual report to the nation on the status of cancer, Part 2: Patient economic burden associated with cancer care. J Natl Cancer Inst. 2021; 113 (19): 1670– 82. https://doi.org/10.1093/jnci/djab192.; Shin G., Kwon H.Y., Bae S. For whom the price escalates: high price and uncertain value of cancer drugs. Int J Environ Res Public Health. 2022; 19 (7): 4204. https://doi.org/10.3390/ijerph19074204.; https://www.pharmacoeconomics.ru/jour/article/view/1226
-
2Academic Journal
Συγγραφείς: Ju. A. Agafonova, A. V. Snegovoy, V. V. Omelyanovskiy, Ю. А. Агафонова, А. В. Снеговой, В. В. Омельяновский
Συνεισφορές: The authors wish to express their deepest gratitude to Aleksandra N. Finyakina for her contribution to the translation and adaptation of part of terms into Russian., Авторы выражают глубокую признательность Финякиной Александре Николаевне за вклад в перевод и адаптацию части терминов на русский язык.
Πηγή: Meditsinskiy sovet = Medical Council; № 22 (2023); 161-171 ; Медицинский Совет; № 22 (2023); 161-171 ; 2658-5790 ; 2079-701X
Θεματικοί όροι: пероральная терапия, compliance, anticancer drugs, anticancer medications, oral drugs, oral therapy, комплаенс, комплаентность, противоопухолевые препараты, пероральные препараты
Περιγραφή αρχείου: application/pdf
Relation: https://www.med-sovet.pro/jour/article/view/7986/7073; Zaugg V, Korb-Savoldelli V, Durieux P, Sabatier B. Providing physicians with feedback on medication adherence for people with chronic diseases taking long-term medication. Cochrane Database Syst Rev. 2018;1:CD012042. https://doi.org/10.1002/14651858.CD012042.pub2.; Лукина ЮВ, Кутишенко НП, Марцевич СЮ, Шепель РН, Драпкина ОМ. Приверженность к лекарственной терапии у больных хроническими неинфекционными заболеваниями. Решение проблемы в ряде клинических ситуаций: методические рекомендации. Профилактическая медицина. 2020;23(3):42–60. Режим доступа: https://www.mediasphera.ru/issues/profilakticheskaya-meditsina/2020/3/downloads/ru/1230549482020032042.; Домбровский ВС, Омельяновский ВВ. Вопросы изучения приверженности лечению: критерии оценки и терминология. Медицинские технологии. Оценка и выбор. 2015;(2):16–23. Режим доступа: https://www.mediasphera.ru/issues/meditsinskie-tekhnologii-otsenka-i-vybor/2015/2.; Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Ollendorf DA et al. Medication compliance and persistence: terminology and definitions. Value Health. 2008;11(1):44–47. https://doi.org/10.1111/j.1524-4733.2007.00213.x.; Lasala R, Santoleri F, Romagnoli A, Abrate P, Musicco F, Costantini A. Medication adherence reporting in pivotal clinical trials: overview of oral oncological drugs. Eur J Hosp Pharm Sci Pract. 2023;30(6):328–332. https://doi.org/10.1136/ejhpharm-2021-002998.; Pantziarka P, Capistrano IR, De Potter A, Vandeborne L, Bouche G. An Open Access Database of Licensed Cancer Drugs. Front Pharmacol. 2021;12:627574. https://doi.org/10.3389/fphar.2021.627574.; Mueller-Schoell A, Groenland SL, Scherf-Clavel O, van Dyk M, Huisinga W, Michelet R et al. Therapeutic drug monitoring of oral targeted antineoplastic drugs. Eur J Clin Pharmacol. 2021;77(4):441–464. https://doi.org/10.1007/s00228-020-03014-8.; Levit LA, Arora S, Kluetz PG, Magnuson A, Rahman A, Harvey RD. Call to Action for Improving Oral Anticancer Agent Adherence. J Clin Oncol. 2022;40(10):1036–1040. https://doi.org/10.1200/JCO.21.02529.; Перечень жизненно необходимых важнейших лекарственных препаратов для медицинского применения на 2021 год. Злокачественные опухоли. 2021;11(3s2-1):598–608. Режим доступа: https://www.malignanttumors.org/jour/article/view/884.; Schlichtig K, Dürr P, Dörje F, Fromm MF. New Oral Anti-Cancer Drugs and Medication Safety. Dtsch Arztebl Int. 2019;116:775–782. https://doi.org/10.3238/arztebl.2019.0775.; Eek D, Krohe M, Mazar I, Horsfield A, Pompilus F, Friebe R et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609–1621. https://doi.org/10.2147/PPA.S106629.; Twelves C, Gollins S, Grieve R, Samuel L. A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/ leucovorin regimens in patients with advanced colorectal cancer. Ann Oncol. 2006;17:239–245. https://doi.org/10.1093/annonc/mdj023.; Ciruelos EM, Díaz MN, Isla MD, López R, Bernabé R, González E et al. Patient preference for oral chemotherapy in the treatment of metastatic breast and lung cancer. Eur J Cancer Care (Engl). 2019;28:e13164. https://doi.org/10.1111/ecc.13164.; Dazzi C, Gamboni A, Delmonte A, Rosetti F, Verlicchi A, Papi M et al. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC: A phase IV study. J Clin Oncol. 2017;35:e20676-e20676. https://doi.org/10.1200/JCO.2017.35.15_suppl.e20676.; Chekerov R, Harter P, Fuxius S, Hanker LC, Woelber L, Müller L et al. Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial. Gynecol Oncol Res Pract. 2017;4:6. https://doi.org/10.1186/s40661-017-0040-2.; Rega ML, Calabrese C, Tortorella P, de Waure C, Damiani G. The Adherence’s indicators of cancer patients to oral chemotherapy. A sistematic literature review. Prof Inferm. 2018;71:67–78. https://doi.org/10.7429/pi.2018.712067.; Hartman L, Lems WF, Boers M. Outcome measures for adherence data from a medication event monitoring system: A literature review. J Clin Pharm Ther. 2019;44:1–5. https://doi.org/10.1111/jcpt.12757.; Puspitasari AW, Kristina SA, Prabandari YS. Overview of Adherence and Influencing Factors to Capecitabine In Cancer Patients: Systematic Review. Int J Pharm Res. 2021;13. https://doi.org/10.31838/ijpr/2021.13.01.476.; Chen Y, Wu X, Xian X, Zhang Y, Gong N, Qin H et al. Adherence to oral chemotherapy among colorectal cancer patients: A longitudinal study. Eur J Oncol Nurs. 2020;48:101822. https://doi.org/10.1016/j.ejon.2020.101822.; Kawakami K, Nakamoto E, Yokokawa T, Sugita K, Mae Y, Hagino A et al. Patients’ self-reported adherence to capecitabine on XELOX treatment in metastatic colorectal cancer: findings from a retrospective cohort analysis. Patient Prefer Adherence. 2015;9:561–567. https://doi.org/10.2147/PPA.S80327.; Greer JA, Amoyal N, Nisotel L, Fishbein JN, MacDonald J, Stagl J et al. A Systematic Review of Adherence to Oral Antineoplastic Therapies. Oncologist. 2016;21:354–376. https://doi.org/10.1634/theoncologist.2015-0405.; Nguyen T-M-U, La Caze A, Cottrell N. What are validated self-report adherence scales really measuring?: a systematic review. Br J Clin Pharmacol. 2014;77:427–445. https://doi.org/10.1111/bcp.12194.; Gast A, Mathes T. Medication adherence influencing factors – an (updated) overview of systematic reviews. Syst Rev. 2019;8:112. https://doi.org/10.1186/s13643-019-1014-8.; Iacorossi L, Gambalunga F, De Domenico R, Serra V, Marzo C, Carlini P. Qualitative study of patients with metastatic prostate cancer to adherence of hormone therapy. Eur J Oncol Nurs. 2019;38:8–12. https://doi.org/10.1016/j.ejon.2018.11.004.; Pilon D, LaMori J, Rossi C, Durkin M, Ghelerter I, Ke X et al. Medication adherence among patients with advanced prostate cancer using oral therapies. Future Oncol. 2022;18:231–243. https://doi.org/10.2217/fon-2021-0992.; Wells KJ, Pan TM, Vázquez-Otero C, Ung D, Ustjanauskas AE, Muñoz D et al. Barriers and facilitators to endocrine therapy adherence among underserved hormone-receptor-positive breast cancer survivors: a qualitative study. Support Care Cancer. 2016;24:4123–30. https://doi.org/10.1007/s00520-016-3229-8.; Verbrugghe M, Verhaeghe S, Decoene E, De Baere S, Vandendorpe B, Van Hecke A. Factors influencing the process of medication (non-)adherence and (non-)persistence in breast cancer patients with adjuvant antihormonal therapy: a qualitative study. Eur J Cancer Care (Engl). 2017;26(2):e12339. https://doi.org/10.1111/ecc.12339.; Nizet P, Touchefeu Y, Pecout S, Cauchin E, Beaudouin E, Mayol S et al. Exploring the factors influencing adherence to oral anticancer drugs in patients with digestive cancer: a qualitative study. Support Care Cancer. 2022;30:2591–2604. https://doi.org/10.1007/s00520-021-06663-2.; Elston Lafata J, Nguyen B, Staresinic C, Johnson M, Gratie D, Muluneh B. Interpersonal communication-, education- and counselling-based interventions to support adherence to oral anticancer therapy: a systematic review. J Oncol Pharm Pract. 2023;29(2):358–369. https://doi.org/10.1177/10781552211073576.; Kaptein AA, Schoones JW, van der Meer PB, Matsuda A, Murray M, Heimans L et al. Psychosocial determinants of adherence with oral anticancer treatment: “we don’t need no education”. Acta Oncol. 2021;60:87–95. https://doi.org/10.1080/0284186X.2020.1843190.; Talens A, Guilabert M, Lumbreras B, Aznar MT, López-Pintor E. Medication Experience and Adherence to Oral Chemotherapy: A Qualitative Study of Patients’ and Health Professionals’ Perspectives. Int J Environ Res Public Health. 2021;18(8):4266. https://doi.org/10.3390/ijerph18084266.; Dowling M, Hunter A, Biesty L, Meskell P, Conway A, O’Boyle G et al. Driving and Disabling Factors of Noncurative Oral Chemotherapy Adherence: A Qualitative Evidence Synthesis. Oncol Nurs Forum. 2019;46:16–28. https://doi.org/10.1188/19.ONF.16-28.; Janse S, Janssen E, Huwig T, Basu Roy U, Ferris A, Presley CJ et al. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment. Curr Med Res Opin. 2021;37:643–653. https://doi.org/10.1080/03007995.2021.1888707.; Skrabal Ross X, Gunn KM, Suppiah V, Patterson P, Olver I. A review of factors influencing non-adherence to oral antineoplastic drugs. Support Care Cancer. 2020;28:4043–4050. https://doi.org/10.1007/s00520-020-05469-y.; Cardoso E, Csajka C, Schneider MP, Widmer N. Effect of Adherence on Pharmacokinetic/Pharmacodynamic Relationships of Oral Targeted Anticancer Drugs. Clin Pharmacokinet. 2018;57:1–6. https://doi.org/10.1007/s40262-017-0571-z.; Santoleri F, Lasala R, Ranucci E, La Barba G, Di Lorenzo R, Vetrò A et al. Medication Adherence to Tyrosine Kinase Inhibitors: 2-Year Analysis of Medication Adherence to Imatinib Treatment for Chronic Myeloid Leukemia and Correlation with the Depth of Molecular Response. Acta Haematol. 2016;136:45–51. https://doi.org/10.1159/000444626.; Boons CCLM, Timmers L, Janssen JJWM, Westerweel PE, Blijlevens NMA, Smit WM et al. Response and Adherence to Nilotinib in Daily practice (RAND study): an in-depth observational study of chronic myeloid leukemia patients treated with nilotinib. Eur J Clin Pharmacol. 2020;76:1213–1226. https://doi.org/10.1007/s00228-020-02910-3.; Lasala R, Santoleri F. Association between adherence to oral therapies in cancer patients and clinical outcome: A systematic review of the literature. Br J Clin Pharmacol. 2022;88:1999–2018. https://doi.org/10.1111/bcp.15147.; Аль-Ради ЛС, Виноградова ОЮ, Кузьмина ЛА, Ломаиа ЕГ, Мартынкевич ИС, Морозова ЕВ и др. Хронический миелоидный лейкоз: клинические рекомендации. 2022. Режим доступа: https://oncology-association.ru/wp-content/uploads/2022/04/hronicheskij-mieloidnyj-lejkoz.pdf.; Inotai A, Ágh T, Maris R, Erdősi D, Kovács S, Kaló Z et al. Systematic review of real-world studies evaluating the impact of medication non-adherence to endocrine therapies on hard clinical endpoints in patients with non-metastatic breast cancer. Cancer Treat Rev. 2021;100(10159):102264. https://doi.org/10.1016/j.ctrv.2021.102264.; Walsh CA, Cahir C, Tecklenborg S, Byrne C, Culbertson MA, Bennett KE. The association between medication non-adherence and adverse health out-comes in ageing populations: A systematic review and meta-analysis. Br J Clin Pharmacol. 2019;85:2464–2478. https://doi.org/10.1111/bcp.14075.; Cutler RL, Fernandez-Llimos F, Frommer M, Benrimoj C, Garcia-Cardenas V. Economic impact of medication non-adherence by disease groups: a systematic review. BMJ Open. 2018;8:e016982. https://doi.org/10.1136/bmjopen-2017-016982.; Murphy M, Bennett K, Ryan S, Hughes CM, Lavan AH, Cadogan CA. A systematic scoping review of interventions to optimise medication prescribing and adherence in older adults with cancer. Res Social Adm Pharm. 2022;18:2392–2402. https://doi.org/10.1016/j.sapharm.2021.04.011.; Talens A, López-Pintor E, Bejerano M, Guilabert M, Aznar MT, Aznar-Lou I et al. Influence of the COVID-19 Pandemic on Adherence to Orally Administered Antineoplastics. J Clin Med. 2022;11(9):2436. https://doi.org/10.3390/jcm11092436.; Cheli S, Lam WWT, Estapé T, Winterling J, Bahcivan O, Andritsch E et al. Risk perception, treatment adherence, and personality during COVID-19 pandemic: An international study on cancer patients. Psychooncology. 2022;31(1):46–53. https://doi.org/10.1002/pon.5775.
-
3Academic Journal
Πηγή: Репродуктивная эндокринология, Vol 0, Iss 56, Pp 13-17 (2020)
Reproductive Endocrinology; № 56 (2020); 13-17
Репродуктивная эндокринология; № 56 (2020); 13-17
Репродуктивна ендокринологія; № 56 (2020); 13-17Θεματικοί όροι: 0301 basic medicine, дефіцит заліза, анемія, феритин, трансферин, аномальні маткові кровотечі, пероральні препарати заліза, заліза бісгліцинат, переносимість, 0303 health sciences, tolerance, ferritin, Gynecology and obstetrics, anemia, 3. Good health, iron bisglycinate, дефицит железа, анемия, ферритин, трансферрин, аномальные маточные кровотечения, пероральные препараты железа, железа бисглицинат, переносимость, 03 medical and health sciences, 0302 clinical medicine, iron deficiency, 5. Gender equality, abnormal uterine bleeding, oral iron preparations, RG1-991, transferrin
Περιγραφή αρχείου: application/pdf
-
4Academic Journal
Συγγραφείς: Belotserkovtseva, L. D., Kovalenko, L. V., Zinin, V. N., Ivannikov, S. E., Keldasova, M. R., Белоцерковцева, Л. Д., Коваленко, Л. В., Зинин, В. Н., Иванников, С. Е., Кельдасова, М. Р.
Θεματικοί όροι: IRON DEFICIENCY ANEMIA, PREGNANCY, SERUM FERRITIN, ORAL IRON PREPARATIONS, COGNITIVE DISORDERS IN CHILDREN, ЖЕЛЕЗОДЕФИЦИТНАЯ АНЕМИЯ, БЕРЕМЕННОСТЬ, СЫВОРОТОЧНЫЙ ФЕРРИТИН, ПЕРОРАЛЬНЫЕ ПРЕПАРАТЫ ЖЕЛЕЗА, КОГНИТИВНЫЕ РАССТРОЙСТВА У ДЕТЕЙ
Περιγραφή αρχείου: application/pdf
Relation: Уральский медицинский журнал. 2023. Т. 22, № 5.; http://elib.usma.ru/handle/usma/17403
Διαθεσιμότητα: http://elib.usma.ru/handle/usma/17403
-
5Academic Journal
Συγγραφείς: A. A. Kolbin, M. V. Naprienko, A. R. Artemenko, I. A. Vilyum, N. V. Latysheva, M. A. Proskurin, Yu. Ye. Balykina
Πηγή: Качественная клиническая практика, Vol 0, Iss 3, Pp 26-44 (2019)
Θεματικοί όροι: мигрень, хроническая мигрень, профилактика мигрени, пероральные препараты для профилактики мигрени, использование ресурсов здравоохранения, ботокс, исследования стоимости болезни, экономическое влияние болезни, анализ влияния на бюджет, Medical technology, R855-855.5, Pharmacy and materia medica, RS1-441
Περιγραφή αρχείου: electronic resource
Relation: https://www.clinvest.ru/jour/article/view/415; https://doaj.org/toc/2588-0519; https://doaj.org/toc/2618-8473
Σύνδεσμος πρόσβασης: https://doaj.org/article/11be59cdc5a4492daddff819d8b2ed1c
-
6Academic Journal
Συγγραφείς: Дедов, Иван, Шестакова, Марина, Сунцов, Юрий, Ягудина, Роза, Крысанов, Иван, Куликов, Андрей, Аринина, Евгения
Θεματικοί όροι: МОДЕЛИРОВАНИЕ, ФАРМАКОЭКОНОМИКА, СТОИМОСТЬ, АНАЛОГИ ИНСУЛИНА, ПЕРОРАЛЬНЫЕ ПРЕПАРАТЫ
Περιγραφή αρχείου: text/html
-
7Academic Journal
Πηγή: Репродуктивна ендокринологія; № 24 (2015); 30-36
Репродуктивная эндокринология; № 24 (2015); 30-36
Reproductive Endocrinology; № 24 (2015); 30-36Θεματικοί όροι: 03 medical and health sciences, железодефицитная анемия, пероральные препараты железа, парентеральные препараты железа, Венофер®, 0302 clinical medicine, залізодефіцитна анемія, пероральні препарати заліза, парентеральні препарати заліза, iron deficiency anemia, oral iron preparations, parenteral iron preparations, Venofer®, 3. Good health
Περιγραφή αρχείου: application/pdf
Σύνδεσμος πρόσβασης: http://reproduct-endo.com/article/view/55184
-
8Academic Journal
Πηγή: Сахарный диабет.
Θεματικοί όροι: 03 medical and health sciences, 0302 clinical medicine, МОДЕЛИРОВАНИЕ, ФАРМАКОЭКОНОМИКА, СТОИМОСТЬ, АНАЛОГИ ИНСУЛИНА, ПЕРОРАЛЬНЫЕ ПРЕПАРАТЫ, 3. Good health
Περιγραφή αρχείου: text/html
-
9Academic Journal
Συγγραφείς: Ушкалова Е.А., Зырянов С.К., Затолочина К.Э.
Πηγή: Profilakticheskaya Meditsina
Θεματικοί όροι: vitamin B12 deficiency, diagnosis, treatment, high-dose oral cyanocobalamin preparations, дефицит витамина B12, диагностика, лечение, высокодозовые пероральные препараты цианокобаламина
Διαθεσιμότητα: https://repository.rudn.ru/records/article/record/80813/
